Summary
The product Testosterone Cypionate, manufactured by Hilma Biocare, was analyzed to assess its composition and potency. The sample was submitted and funded by hilmabiocare.com and tested by Janoshik Analytical, a trusted laboratory known for its analytical accuracy. The analysis confirmed the presence of Testosterone Cypionate at a measured concentration of 241.71 mg/ml, which is slightly below the labeled specification of 250 mg/ml, reflecting a 3.32% variance below the label claim.
Testing was initiated on 11 January 2024, the sample was received on 23 January 2024, and the analysis was completed on 26 January 2024. While the minor variance indicates acceptable quality control, caution is advised due to the manufacturer’s involvement in submitting the sample, which could introduce potential biases. Independent third-party testing of market-procured samples is recommended to validate the product’s consistency.
Detailed Report
Product Overview
- Manufacturer: Hilma Biocare
- Product Name: Testosterone Cypionate
- Active Ingredient: Testosterone Cypionate
- Batch Number: Testosterone Cypionate – 0210
- Expiration Date: Not provided
- Delivery Method: Injectable
Sample Acquisition and Testing
- Task Number: #37749
- Testing Ordered: 11 January 2024
- Sample Received: 23 January 2024
- Analysis Conducted By: Janoshik Analytical
- Product Submitted By: hilmabiocare.com (Manufacturer)
- Analysis Paid For By: hilmabiocare.com
Testing Results
- Specification: 250 mg/ml (as stated on the label)
- Measured Concentration: 241.71 mg/ml
- Accuracy: 96.68% (3.32% below the label claim)
Verification Details
- Verification URL: https://janoshik.com/tests/37749_UFAGJA8P11TQ
- Originally Published: https://thinksteroids.com/community/posts/3229470/
Evaluation of Manufacturer-Submitted Testing
The report highlights a high level of dosing accuracy in this batch of Testosterone Cypionate, with a 3.32% variance below the label claim. However, because the sample was submitted and funded by the manufacturer, hilmabiocare.com, there is a potential for selective sample submission. While this does not inherently undermine the results, third-party testing of market-purchased samples is essential to ensure consistency and transparency.
Conclusion
The analysis demonstrates that Testosterone Cypionate maintains reliable dosing accuracy, with a minor variance of 3.32% below the labeled claim. The findings suggest strong quality control, but independent verification through third-party testing of randomly procured products remains critical for enhanced consumer trust and harm reduction.
Disclaimer
This report is published for educational and harm reduction purposes. Manufacturer-submitted testing may involve inherent biases due to selective sample submissions. The findings pertain solely to the tested batch and may not represent all products under the same name. Readers are encouraged to cross-reference these results with independent third-party testing for additional validation and use this information responsibly.
